| 2017 | Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial
| INTERNATIONAL JOURNAL OF CANCER |
| 2017 | Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer
| ONCOLOGY LETTERS |
| 2016 | p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer
| CANCER RESEARCH AND TREATMENT |
| 2015 | A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS |
| 2015 | Leiomyosarcoma: investigation of prognostic factors for risk-stratification model | INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY |
| 2015 | Novel methods for clinical risk stratification in patients with colorectal liver metastases
| CANCER RESEARCH AND TREATMENT |
| 2015 | Secondary malignant neoplasms after osteosarcoma: early onset and cumulative alkylating agent dose dependency | ANNALS OF SURGICAL ONCOLOGY |
| 2015 | Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children
| CANCER RESEARCH AND TREATMENT |
| 2014 | Vascular Soft-Tissue Sarcomas: A Prognostic Model from a Retrospective Single-Center Study | ONCOLOGY |
| 2014 | Japanese Cancer Association Meeting UICC International Session - What is Cost-effectiveness in Cancer Treatment?
| ASIAN PACIFIC JOURNAL OF CANCER PREVENTION |
| 2014 | Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study | JOURNAL OF CLINICAL PATHOLOGY |
| 2013 | Prognostic Value of Mucinous Histology Depends on Microsatellite Instability Status in Patients with Stage III Colon Cancer Treated with Adjuvant FOLFOX Chemotherapy: A Retrospective Cohort Study | ANNALS OF SURGICAL ONCOLOGY |
| 2013 | Changing treatment patterns in elderly patients with resectable colon cancer | ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY |
| 2013 | Combination of CYP inhibitor with MEK/ERK inhibitor enhances the inhibitory effect on ERK in BRAF mutant colon cancer cells. | ANTICANCER RESEARCH |
| 2013 | Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors
| SUPPORTIVE CARE IN CANCER |
| 2013 | Application of the Adjuvant! Online Model to Korean Breast Cancer Patients: An Assessment of Prognostic Accuracy and Development of an Alternative Prognostic Tool | ANNALS OF SURGICAL ONCOLOGY |
| 2013 | Union for International Cancer Control International Session: Healthcare Economics: The significance of the UN summit non-communicable diseases political declaration in Asia | CANCER SCIENCE |
| 2013 | Estimating the Adjuvant Chemotherapy Effect in Elderly Stage II and III Colon Cancer Patients in an Observational Study | JOURNAL OF SURGICAL ONCOLOGY |
| 2013 | Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent | INVESTIGATIONAL NEW DRUGS |
| 2012 | Implications of clinical risk score to predict outcomes of liver-confined metastasis of colorectal cancer | SURGICAL ONCOLOGY-OXFORD |
| 2012 | Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group | JOURNAL OF CLINICAL ONCOLOGY |
| 2012 | A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy. | INVESTIGATIONAL NEW DRUGS |
| 2012 | A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. | INVESTIGATIONAL NEW DRUGS |
| 2012 | VIPoma that arose from the rectum in a 65-year-old male patient. | INTERNATIONAL JOURNAL OF COLORECTAL DISEASE |
| 2012 | Methylation status of lamin A/C in gastric cancer cell lines. | HEPATO-GASTROENTEROLOGY |
| 2012 | Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma: a retrospective analysis.
| CANCER RESEARCH AND TREATMENT |
| 2012 | Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience.
| BMC CANCER |
| 2012 | Quantitative analysis of ERK signaling inhibition in colon cancer cell lines using phospho-specific flow cytometry | ANALYTICAL AND QUANTITATIVE CYTOPATHOLOGY AND HISTOPATHOLOGY |
| 2011 | Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis | ONCOLOGY |
| 2011 | Advanced detection of recent changing trends in gastric cancer survival: up-to-date comparison by period analysis.
| JAPANESE JOURNAL OF CLINICAL ONCOLOGY |
| 2011 | Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity | ONCOLOGY |
| 2011 | Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer
| CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2011 | Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer | INVESTIGATIONAL NEW DRUGS |
| 2011 | Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer | ANTI-CANCER DRUGS |
| 2011 | A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy
| CANCER |
| 2011 | Genome-wide molecular characterization of mucinous colorectal adenocarcinoma using cDNA microarray analysis. | ONCOLOGY REPORTS |
| 2011 | Brain metastases from colorectal carcinoma: prognostic factors and outcome | JOURNAL OF NEURO-ONCOLOGY |
| 2010 | Clinicopathologic features of metachronous or synchronous gastric cancer patients with three or more primary sites
| CANCER RESEARCH AND TREATMENT |
| 2010 | The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up | ANNALS OF SURGICAL ONCOLOGY |
| 2010 | Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2010 | Chemokine growth-regulated oncogene 1 as a putative biomarker for gastric cancer progression | CANCER SCIENCE |
| 2010 | A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer | INVESTIGATIONAL NEW DRUGS |
| 2010 | Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2010 | Adenocarcinoma of the small bowel at a single Korean institute: management and prognosticators | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY |
| 2010 | Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer | RADIOTHERAPY AND ONCOLOGY |
| 2010 | A phase II study of a combined biweekly irinotecan and monthly cisplatin treatment for metastatic or recurrent gastric cancer. | AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS |
| 2010 | Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer
| JAPANESE JOURNAL OF CLINICAL ONCOLOGY |
| 2010 | Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients | CANCER LETTERS |
| 2009 | A phase II feasibility study of weekly paclitaxel in heavily pretreated advanced gastric cancer patients with poor performance status | ONCOLOGY |
| 2009 | Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. | LANCET |
